A1 Pharmaceuticals Plc

Latest News >>

A1 Pharmaceuticals Plc finalist in the Havering Business Awards 2014A1 listed in Sunday Times Profit Track 100A1 Pharmaceuticals Plc wins the highest business award in East LondonA1 Pharmaceuticals Plc declared as a National Champion in the European Business Awards 2013 – 20142013 Essex Countrywide Business Awards – A1 is Growing Business of the YearA1 Pharmaceuticals Plc declared Finalists in the European Business Awards 2012A1 Pharmaceuticals Plc recognised in Queen’s Birthday honours list 2012National Sales Awards 2004 – Sales Professional of the Year AwardNational Business Awards 2009 – Growth Strategy of the Year AwardNational Business Awards 2009 – Entrepreneur of the Year FinalistsErnst & Young Entrepreneur of year Winner 2007National Business Awards 2010- Entrepreneur of the Year FinalistsChamber Award 2011 – Achievement in International BusinessSunday Times International Fast Track 100 (2011) and Fast Track 200 (2012)

Managing Director’s financial strategic report 2017

1st September 2017

Managing Director Gary Stephen Lewis MRPharmS Financial & Strategic report for A1 Pharmaceuticals Plc for the year ended 30th April 2017.

Business review:

The company continues to demonstrate strong sales with an improvement of 2.6% on the previous year to record annual sales of £55.6 million. Annual sales have consistently been above £50 million since 2014.

The financial strength of the company remains very strong with net assets and working capital increasing to a record £11.2 million up by a significant 28.7% on the previous year and a huge 62% increase since 2014.

Principal risks and uncertainties:

The key business risk and uncertainties affecting the company are considered to relate to the uncertainty of ‘Brexit’ and normal competition in the market place.

Although the company is very much committed to the concept of the European Union it has a 30 year history of utilising adversity as a stimulus to growth.

After completing the first quarter of the new financial year sales are once again expected to exceed £55 million in spite of weak sterling, assets are expected to grow to record levels in excess of £13 million by year end April 2018. The credit rating of the company is expected to increase for the 6th consecutive year when our accounts are filed at companies house in September 2017.

Credit rating:

Creditsafe* recommend £1.15 million credit limit a numerical rating of 80 (70+ excellent very low risk) which places the company in the top 25% in the UK. The international score is grade A the highest grade possible and the company is considered one of the promptest payers in the pharmaceutical and healthcare sector. *Creditsafe is endorsed by all major credit insurers meaning their ratings & limits are one of the most trusted globally.

Opportunities:

The company continues to reinvest in people and new technology and with its growing financial strength is keen to consider Merger and Acquisition of companies and/or products within the healthcare and Pharmacy sector globally. The company will continue to recruit and invest in training and development of its people.

Financial key performance:

Although pre-tax profit is down on last year to £3.3 million it’s still extremely healthy and in the top 5 annual performances of a 30 year history, importantly both sales turnover (£55.6 million) and Net assets/working capital (£11.2 million) have both grown to record levels.

The Directors’ would like to thank their growing team, suppliers and customers including our auditors Barnes Roffe that have made another successful year possible.

« Back to News
Facebook Iconfacebook like buttonTwitter Icontwitter follow button